One of the largest Russian distributors and manufacturers of medicines – the group of companies R-Pharm – will create a network of centers for functional and genetic diagnostics, the RNS website reported. The agreement on this was signed on January 9, 2018 with an American company specializing in the analysis of genetic data – Human Longevity, a representative of R-Pharma told Vedomosti. The contract is unlimited, the amount of the transaction was not disclosed.
The representative of Human Longevity has not yet responded to the request of Vedomosti.
Thanks to the study of the human genome, it is possible to create more effective drugs that can radically improve the quality and duration of human life, the representative of R-Pharma points out. “We bought from Human Longevity technology and pay it for their use,” continues the representative of the Russian company, without disclosing the amount.
“R-Pharm” will engage in genetic analysis for patients and on their basis will be able to improve production and selection of drugs, a person familiar with the plans of companies knows.
In Russia, it is planned to build two centers, the representative of the Russian pharmaceutical company added: the first will be launched in 2019 in the Central Federal District, the site has not yet been determined. The creation of each center will cost about $ 15 million.
In 2016, the revenue of R-Pharma amounted to 71.1 billion rubles. The company is the largest supplier of drugs to the state: in 2016 it had 10.3% of the market, according to Quintiles IMS.
Author: Anastasia Ivanova
Article in Russian: Vedomosti